




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

available at [www.sciencedirect.com](http://www.sciencedirect.com)  
journal homepage: [www.europeanurology.com](http://www.europeanurology.com)



## Letter to the Editor

**Reply to Yu Wei, Yao Zhu, and Dingwei Ye's Letter to the Editor re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022;82:6–11**

We thank Zhu et al for their interest in our recent article [1]. At the Advanced Prostate Cancer Consensus Conference 2021 (APCCC 2021) the panel voted on questions regarding prostate cancer management during the COVID-19 pandemic but there was no specific question about patients enrolled in clinical trials.

The APCCC panel reached a strong consensus (agreement of 97% of panelists) that COVID-19 vaccination should be recommended for all patients with advanced prostate cancer. Accordingly, we agree with the suggestion that COVID-19 vaccination should also be recommended to the subset of patients with advanced prostate cancer who enrol in clinical trials. But we strongly believe that the recommendation for vaccination should not be limited to this subgroup of patients.

In the ARASENS trial, the risk of death was 32.5% lower in the darolutamide group than in the placebo group (hazard ratio 0.68, 95% confidence interval 0.57–0.80;  $p < 0.001$ ) [2]. The prespecified primary analysis for overall survival was carried out after a total of 533 deaths were observed. The six deaths attributed to COVID-19 represent less than 1.1% of all deaths and had no meaningful impact on the study results.

### Conflicts of interest

Fabio Turco and Matthew Smith have nothing to disclose. Aurelius Omlin has received institutional advisory fees from AstraZeneca, Astellas, Bayer, Janssen, Molecular Partners, MSD, Pfizer, Roche, and Sanofi Aventis; institutional research support from TEVA and Janssen; travel support from Astellas, Bayer, Janssen, and Sanofi Aventis; and institutional speaker bureau fees from Bayer, Astellas, and Janssen. Silke Gillessen has received personal honoraria for participation in advisory boards from Sanofi, Orion, Roche, Amgen, and MSD, and other honoraria from Televisione Svizzera Italiana; has been an invited speaker

for ESMO, the Swiss Group for Clinical Cancer Research (SAKK), the Swiss Academy of Multidisciplinary Oncology (SAMO), the Orikata Academy Research Group, and the China Anti-Cancer Association Genitourinary Oncology Committee (CACA-GU); participates in a speaker bureau for Janssen Cilag; has received a travel grant from ProteoMEDIx; has received institutional honoraria for participation in advisory boards from Bayer, Janssen Cilag, Roche, AAA International, Amgen, Menarini Silicon Biosystems, Astellas Pharma, Tolero Pharmaceuticals, MSD, Pfizer, Telixpharma, BMS, and Orion; and holds patent royalties and other intellectual property for a research method for a biomarker (WO2009138392).

### References

- [1] Turco F, Armstrong A, Attard G, et al. What experts think about prostate cancer management during the COVID-19 pandemic: report from the Advanced Prostate Cancer Manuscript Click here to view linked References Consensus Conference 2021. *Eur Urol.* 2022;82:6–11.
- [2] Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. *N Engl J Med.* In press. <https://doi.org/10.1056/NEJMoa2119115>.

F. Turco<sup>a,b,\*</sup>  
M. Smith<sup>c</sup>  
A. Omlin<sup>d,h</sup>  
S. Gillessen<sup>e,f,g,h,i</sup>

- <sup>a</sup> Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland  
<sup>b</sup> Department of Oncology, University of Turin, Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy  
<sup>c</sup> Massachusetts General Hospital Cancer Center, Boston, MA, USA  
<sup>d</sup> Department of Medical Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland  
<sup>e</sup> Oncology Institute of Southern Switzerland, Bellinzona, Switzerland  
<sup>f</sup> Università della Svizzera Italiana, Lugano, Switzerland  
<sup>g</sup> Cantonal Hospital, St. Gallen, Switzerland  
<sup>h</sup> University of Bern, Bern, Switzerland  
<sup>i</sup> Division of Cancer Science, University of Manchester, Manchester, UK

\*Corresponding author. Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.  
E-mail address: [turcofabio9@gmail.com](mailto:turcofabio9@gmail.com) (F. Turco).

March 24, 2022

DOI of original article: <https://doi.org/10.1016/j.eururo.2022.03.030>

<https://doi.org/10.1016/j.eururo.2022.03.029>

0302-2838/© 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.

